Tiziana Life Sciences Ltd Dossier - Source-backed chat

Tiziana Life Sciences Ltd

TLSANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.69

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.11Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $141.3M

Enterprise Value $137.5M

Shares Outstanding 106.7M diluted

Next Earnings Date31 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Tiziana Life Sciences is a clinical-stage biopharmaceutical company uniquely positioned in the neurodegenerative and neuroinflammatory space with its lead candidate, intranasal foralumab. As the only fully human anti-CD3 monoclonal antibody in clinical development, foralumab targets neuroinflammation by stimulating regulatory T cells (Tregs) via a non-invasive nasal delivery route. The company has successfully completed enrollment in its randomized, double-blind, placebo-controlled Phase 2a trial (INFORM-MS) for non-active Secondary Progressive Multiple Sclerosis (na-SPMS), with highly anticipated topline data expected in late Q3 2026. Early data from its Expanded Access program and pilot studies in Multiple System Atrophy (MSA) and Alzheimer's disease demonstrate a favorable safety profile and significant reductions in brain inflammation, supporting a robust platform potential. While financial constraints and going concern risks remain typical for clinical-stage biotechs, the upcoming clinical catalysts present a highly asymmetric risk-reward profile for investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.08

Mean target$9.08

High · most bullish analyst$9.08

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5025%

The Phase 2a trial fails to show a statistically significant difference in microglial activation or clinical outcomes compared to the placebo arm. Safety concerns or tolerability issues emerge over extended dosing. The company is unable to secure additional financing or partnerships, leading to severe dilution through emergency equity offerings or a halt in clinical development.

Base CaseCentral scenario

$9.0855%

Matches the consensus mean

The Phase 2a INFORM-MS trial meets its primary safety and biomarker endpoints (demonstrating a reduction in microglial activation via PET imaging and stabilization of disability). The positive data de-risks the platform, paving the way for a registrational Phase 3 trial in na-SPMS and accelerating development in secondary indications like Alzheimer's and MSA. Tiziana secures a strategic partnership or non-dilutive licensing deal to extend its cash runway.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Unique mechanism of action as the only fully human anti-CD3 monoclonal antibody in clinical development.
Innovative intranasal delivery route that directly targets the brain's immune mechanisms, bypassing systemic side effects of intravenous administration.
Completed enrollment of 48 patients in the Phase 2a INFORM-MS trial, locking in a clear near-term clinical catalyst in late Q3 2026.
Encouraging clinical signals from the Expanded Access program, where 64% of na-SPMS patients achieved clinically meaningful improvements in fatigue.
Broad platform applicability across high-value indications including Multiple Sclerosis, Alzheimer's disease, Multiple System Atrophy, and ALS.

Key Investment Risks

High clinical development risk typical of early-stage biopharmaceutical companies, with no approved products or commercial revenues.
Going concern risk with a cash balance of $4.0 million and a working capital deficit of $2.7 million as of December 31, 2025.
Dependence on a single lead candidate (foralumab) for the majority of the pipeline's valuation.
Potential for significant shareholder dilution to fund late-stage clinical trials.

Thesis Invalidation Triggers

Failure of the INFORM-MS Phase 2a trial to meet its primary endpoints or show differentiation from placebo.
Inability to raise sufficient capital to fund operations beyond the next 12 months, leading to insolvency or distressed asset sales.
Regulatory holds or safety halts imposed by the FDA on the foralumab clinical programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.